Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open Label, Multicenter Phase II/III Trial of Sacituzumab Govitecan Compared to Standard of Care in Metastatic, Refractory Colorectal Cancer Patients

NCT06243393 is registered in ClinicalTrials.gov with University Hospital Heidelberg as lead sponsor.

NCT NCT06243393
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06243393 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open Label, Multicenter Phase II/III Trial of Sacituzumab Govitecan Compared to Standard of Care in Metastatic, Refractory Colorectal Cancer Patients
Lead sponsor
University Hospital Heidelberg
Phase
Phase 2/3
Overall status
Recruiting
Start date
April 19, 2024
Completion date
February 1, 2029
Enrollment
80 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic colorectal cancer